Soluble ST2 in Coronary Artery Disease: Clinical Biomarkers and Treatment Guidance

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Oct 13

PMID 36225958

Authors

Junyan Zhang

Zhongxiu Chen

Min Ma

Yong He

Affiliations

Soon will be listed here.

Abstract

The IL-33/ST2 L signaling pathway is involved in the pathophysiological processes of several diseases and mainly exerts anti-inflammatory and antifibrotic effects. Soluble suppression of tumorigenicity 2 (sST2), which serves as a competitive inhibitory molecule of this pathway, is a member of the interleukin (IL)-1 family, a decoy receptor for IL33, thought to play a role in cardiac remodeling and the inflammatory process. However, the association between sST2 and coronary artery disease (CAD), one of the most common causes of heart failure, is still being explored. We therefore reviewed the research on sST2 in the field of CAD, including reflecting the atherosclerosis burden, predicting no-reflow, predicting prognosis, responding to myocardial remodeling, and guiding management, hoping to provide cardiologists with new perspectives.

Citing Articles

Elevated Soluble Suppressor of Tumorigenicity 2 Levels in Gout Patients and Its Association with Cardiovascular Disease Risk Indicators.

Kim J, Lee J, Bae K, Ahn S Yonsei Med J. 2025; 66(3):151-159.

PMID: 39999990 PMC: 11865869. DOI: 10.3349/ymj.2024.0001.

IL-33/soluble ST2 axis is associated with radiation-induced cardiac injury.

Yasen X, Aikebaier R, Maimaiti A, Mushajiang M Open Life Sci. 2024; 19(1):20220841.

PMID: 38585634 PMC: 10997150. DOI: 10.1515/biol-2022-0841.

Chronic Kidney Disease Associated with Ischemic Heart Disease: To What Extent Do Biomarkers Help?.

Cepoi M, Duca S, Chetran A, Costache A, Spiridon M, Afrasanie I Life (Basel). 2024; 14(1).

PMID: 38255650 PMC: 10817293. DOI: 10.3390/life14010034.

Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide.

Riccardi M, Myhre P, Zelniker T, Metra M, Januzzi J, Inciardi R J Cardiovasc Dev Dis. 2023; 10(11).

PMID: 37998526 PMC: 10672197. DOI: 10.3390/jcdd10110468.

Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome.

Katsioupa M, Kourampi I, Oikonomou E, Tsigkou V, Theofilis P, Charalambous G Life (Basel). 2023; 13(10).

PMID: 37895374 PMC: 10608753. DOI: 10.3390/life13101992.

References

Sabatine M, Morrow D, Higgins L, Macgillivray C, Guo W, Bode C . Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008; 117(15):1936-44. PMC: 4273564. DOI: 10.1161/CIRCULATIONAHA.107.728022. View

Pecherina T, Kutikhin A, Kashtalap V, Karetnikova V, Gruzdeva O, Hryachkova O . Serum and Echocardiographic Markers May Synergistically Predict Adverse Cardiac Remodeling after ST-Segment Elevation Myocardial Infarction in Patients with Preserved Ejection Fraction. Diagnostics (Basel). 2020; 10(5). PMC: 7278008. DOI: 10.3390/diagnostics10050301. View

Lingel A, Weiss T, Niebuhr M, Pan B, Appleton B, Wiesmann C . Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure. 2009; 17(10):1398-410. PMC: 2766095. DOI: 10.1016/j.str.2009.08.009. View

Yousef Z, Redwood S, Marber M . Postinfarction left ventricular remodelling: where are the theories and trials leading us?. Heart. 2000; 83(1):76-80. PMC: 1729255. DOI: 10.1136/heart.83.1.76. View

Biere L, Garcia G, Guillou S, Larcher F, Furber A, Willoteaux S . ST2 as a predictor of late ventricular remodeling after myocardial infarction. Int J Cardiol. 2018; 259:40-42. DOI: 10.1016/j.ijcard.2018.02.058. View

Zhang Q, Hu M, Ma S . Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention. J Atheroscler Thromb. 2021; 28(12):1289-1297. PMC: 8629709. DOI: 10.5551/jat.59832. View

Homsak E, Gruson D . Soluble ST2: A complex and diverse role in several diseases. Clin Chim Acta. 2020; 507:75-87. DOI: 10.1016/j.cca.2020.04.011. View

Oh J, Park S, Yu H, Chang H, Lee S, Kang S . Lack of Superiority for Soluble ST2 over High Sensitive C-Reactive Protein in Predicting High Risk Coronary Artery Calcium Score in a Community Cohort. Yonsei Med J. 2016; 57(6):1347-53. PMC: 5011265. DOI: 10.3349/ymj.2016.57.6.1347. View

Dieplinger B, Egger M, Haltmayer M, Kleber M, Scharnagl H, Silbernagel G . Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin Chem. 2014; 60(3):530-40. DOI: 10.1373/clinchem.2013.209858. View

10.

Lu D, Zhou X, Yao L, Liu C, Ma W, Jin F . Serum soluble ST2 is associated with ER-positive breast cancer. BMC Cancer. 2014; 14:198. PMC: 3995159. DOI: 10.1186/1471-2407-14-198. View

11.

Luo G, Qian Y, Sheng X, Sun J, Wu Z, Liao F . Elevated Serum Levels of Soluble ST2 Are Associated With Plaque Vulnerability in Patients With Non-ST-Elevation Acute Coronary Syndrome. Front Cardiovasc Med. 2021; 8:688522. PMC: 8341076. DOI: 10.3389/fcvm.2021.688522. View

12.

Madhavan M, Gersh B, Alexander K, Granger C, Stone G . Coronary Artery Disease in Patients ≥80 Years of Age. J Am Coll Cardiol. 2018; 71(18):2015-2040. DOI: 10.1016/j.jacc.2017.12.068. View

13.

Pfetsch V, Sanin V, Jaensch A, Dallmeier D, Mons U, Brenner H . Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study. Cardiovasc Drugs Ther. 2017; 31(2):167-177. DOI: 10.1007/s10557-017-6718-1. View

14.

Boga S, Alkim H, Koksal A, Ozagari A, Bayram M, Neijmann S . Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity. J Investig Med. 2016; 64(5):1016-24. DOI: 10.1136/jim-2016-000062. View

15.

Aimo A, Januzzi Jr J, Bayes-Genis A, Vergaro G, Sciarrone P, Passino C . Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 74(17):2193-2203. DOI: 10.1016/j.jacc.2019.08.1039. View

16.

Tian J, Ren X, Vergallo R, Xing L, Yu H, Jia H . Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study. J Am Coll Cardiol. 2014; 63(21):2209-16. DOI: 10.1016/j.jacc.2014.01.061. View

17.

Somuncu M, Akgun T, Cakir M, Akgul F, Serbest N, Karakurt H . The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J Atheroscler Thromb. 2019; 26(11):970-978. PMC: 6845696. DOI: 10.5551/jat.48413. View

18.

Pei C, Barbour M, Fairlie-Clarke K, Allan D, Mu R, Jiang H . Emerging role of interleukin-33 in autoimmune diseases. Immunology. 2013; 141(1):9-17. PMC: 3893845. DOI: 10.1111/imm.12174. View

19.

Gaggin H, Motiwala S, Bhardwaj A, Parks K, Januzzi Jr J . Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Circ Heart Fail. 2013; 6(6):1206-13. DOI: 10.1161/CIRCHEARTFAILURE.113.000457. View

20.

Shimpo M, Morrow D, Weinberg E, Sabatine M, Murphy S, Antman E . Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004; 109(18):2186-90. DOI: 10.1161/01.CIR.0000127958.21003.5A. View